GlassScriptPhysician profile
Joey Romar
NPI 1396191979
$3,199.76
in general payments reported to CMS, 2019-2025
29 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $13.43 · 2021: $210 · 2022: $419 · 2023: $761 · 2024: $849 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.72 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $406.11 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $400.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $271.15 | 2021-2025 | Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $246.42 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.89 | 2019-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $150.35 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $144.83 | 2021-2025 | |
| Amgen INC. | $91.18 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $85.21 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.07 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $80.33 | 2022-2025 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $66.22 | 2023-2024 | Veozah |
| Sanofi Pasteur INC. | $61.38 | 2022-2024 | |
| Dexcom, INC. | $59.36 | 2022-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.54 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.09 | 2022 | |
| Pfizer INC. | $47.97 | 2019-2024 | |
| Glaxosmithkline, LLC. | $44.27 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $31.79 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $28.76 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $26.77 | 2020-2021 | |
| Daiichi Sankyo INC. | $21.07 | 2025 | Injectafer |
| Shield Therapeutics INC | $18.09 | 2023 | Accrufer |
| Seqirus USA INC | $15.88 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biohaven Pharmaceuticals, INC. | $14.08 | 2021 | |
| Amarin Pharma, INC. | $13.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.54 | 2022 | |
| Dynavax Technologies Corporation | $13.34 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joey Romar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.